Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
Completed
Boehringer Ingelheim
Phase 3
2005-03-01
The purpose of this study is to assess the efficacy and safety of duloxetine compared with
placebo in the prevention of depressive recurrences among patients with recurrent major
depressive disorder.
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
Completed
Eli Lilly and Company
Phase 3
2005-03-01
The purpose of this study is to assess the efficacy and safety of duloxetine compared with
placebo in the prevention of depressive recurrences among patients with recurrent major
depressive disorder.
Antidepressant Medication Plus Donepezil for Treating Late-life Depression
Completed
National Institute of Mental Health (NIMH)
Phase 4
2003-12-01
This study will determine the effectiveness of combining escitalopram, venlafaxine, or
duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory,
concentration, attention, and problem solving abilities, and reducing the risk of depressive
relapse in older individuals with depression.
Antidepressant Medication Plus Donepezil for Treating Late-life Depression
Completed
University of Pittsburgh
Phase 4
2003-12-01
This study will determine the effectiveness of combining escitalopram, venlafaxine, or
duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory,
concentration, attention, and problem solving abilities, and reducing the risk of depressive
relapse in older individuals with depression.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
